Richard Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
August 20, 2021 07:07 AM EDTUpdated 08:40 AM
Pharma

Court up­holds Ab­b­Vie's patents on block­buster can­cer drug Im­bru­vi­ca, gener­ics un­like­ly un­til 2032

Zachary Brennan

Senior Editor

Ab­b­Vie’s block­buster can­cer drug Im­bru­vi­ca may hold on­to its mo­nop­oly for at least an­oth­er decade, thanks to a court rul­ing Thurs­day that found a gener­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times